The company will permit six generic drugmakers to make and sell lenacapavir in 120 countries that have high incidence of the disease, but limited resources.

Professor of medicine and deputy director of the Desmond Tutu HIV Centre at the Institute of Infectious Disease and Molecular Medicine, University of Cape Town A new drug to prevent HIV infection ...

A small French biotech is trumpeting results from a trial suggesting its developmental drug could be used as part of an HIV cure ... Ehrlich said: “The new findings of the ABVX-005 study ...

The antiretroviral drug has been hailed as a potential game ... There were 1.3 million new HIV infections last year, while 39 million people are living with the virus, according to the World ...

Since the FDA approved the drug in 2012, more people have started to use it, and HIV rates have steadily decreased. However, not everyone sees the same results. The South had 53% of new HIV ...

Future modifications of the GSS/PSS scores and of bioinformatics-based methods are needed to improve the choice of optimized therapy in pivotal studies of new HIV drugs and in the clinical care of ...

Gilead sells a number of widely used HIV medicines and, with lenacapavir, aims to add a new kind of drug to physicians’ arsenal. The company plans to begin global regulatory filings for ...